Skip to main content
. Author manuscript; available in PMC: 2012 Sep 22.
Published in final edited form as: Adv Mater. 2011 Aug 15;23(36):H217–H247. doi: 10.1002/adma.201102313

Figure 17.

Figure 17

Treatment of cancer stem cells (CSCs). Standard chemotherapy agents debulk the tumor, but can leave residual drug resistant CSCs which will lead to relapse. A CSC targeted therapy that can selectively and efficiently kill the CSCs will leave a benign mass.